New combo pill shows promise for diabetes control in japanese patients
NCT ID NCT00974090
First seen Jan 10, 2026 · Last updated May 25, 2026 · Updated 22 times
Summary
This study tested a new drug, MP-513 (Teneligliptin), added to standard sulfonylurea treatment in 194 Japanese adults with type 2 diabetes. The goal was to see if the combination improved blood sugar levels more than sulfonylurea alone over 12 weeks, with a follow-up up to 52 weeks. Participants had moderate diabetes and were already on sulfonylurea. The study is complete, and results focus on changes in HbA1c and fasting glucose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Sapporo, Hokkaido, Japan
Conditions
Explore the condition pages connected to this study.